All posts by: Gretchen Temeles

About Gretchen Temeles

Cannabis Rescheduling: Over 43,000 Weigh In

September 5, 2024 Cannabis Law

In the May and June newsletters, we wrote about a proposal by the U.S. Department of Justice (DOJ) to transfer marijuana from Schedule I to Schedule III. Under the Controlled Substances Act (CSA), Schedule I substances are considered to have no currently accepted medical use and a high potential for abuse.  Possession and sale of cannabis is illegal under U.S. federal […]

IP Protection of Psychedelics

August 8, 2024 Patent

The past few years have witnessed astonishing growth in commercial interest in the use of psychedelics for treatment of a variety of unmet medical needs, particularly mental health disorders.  With that growth has come an increase in patent filings as companies seek to protect their investments.  IP protection for psychedelics and psychedelic-related compounds shares many […]

Cannabis Scheduling and Rescheduling: Part I

June 27, 2024 Uncategorized

Another Long Strange Trip In 1970, the U.S. Congress enacted the Controlled Substances Act (CSA) to establish a federal drug policy regulating the manufacture and distribution of regulated substances. The CSA classified cannabis (the CSA schedule refers to marijuana and cannabis interchangeably.) as a Schedule I controlled substance. Schedule I substances are considered to have […]

Welcome Gretchen L. Temeles, Ph.D., J.D.

June 6, 2024 Uncategorized

A new lawyer has joined the ranks of Lipton, Weinberger & Husick. So, welcome our new partner, Gretchen L. Temeles, Ph.D., J.D. Gretchen arrives at our firm with experience that will greatly complement our patent prosecution and related practice. Here’s an overview of her experience: Gretchen is an experienced intellectual property attorney and scientist. She […]

Trade Secret Litigation Comes to Psychedelics

September 6, 2022 Trade Secrets

In contrast to medical science’s aggressive pursuit of new therapeutics for cancers, cardiovascular disorders, or infectious disease, the discovery of new therapeutics for mental health has lagged. But, the past few years have witnessed renewed interest in the development of psychedelic therapeutics for treatment of unmet medical needs in mental health. The astonishing growth of a […]

Contact Adam Garson, Esq.

  • National Client Base
  • 610-565-7630

Sign-up for Monthly Emails

* indicates required

Top Rated

Lawyer Adam Garson | Top Attorney Trademark Application

Connect on Social Media

Recent News

Search this Website